Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.81% | 19.54% | 8.06% | -1.59% | -3.33% |
| Total Depreciation and Amortization | -67.04% | -44.38% | -25.57% | -5.69% | -5.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.49% | -67.27% | -62.11% | -53.98% | -53.53% |
| Change in Net Operating Assets | -101.93% | -145.97% | 201.02% | 429.71% | 354.37% |
| Cash from Operations | -12.85% | -13.47% | 1.34% | -15.15% | -12.04% |
| Capital Expenditure | 100.00% | 99.70% | 100.00% | 100.00% | 83.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 341.18% | -43.12% | 254.60% | 248.95% | -201.00% |
| Cash from Investing | 338.84% | -35.41% | 245.47% | 239.77% | -209.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.75% | 133.65% | -92.84% | -91.68% | -90.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 121.53% | 100.00% | 100.00% | 100.00% |
| Cash from Financing | 256.84% | 510.81% | -84.93% | -91.54% | -90.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.89% | -8.26% | 48.88% | -100.65% | -274.29% |